David Collingridge a Visiting Professor of Global Oncology at King’s College London and Editor-in-Chief of The Lancet Oncology, a role he has held since 2002. He also serves as Vice President for Editorial Strategy and Innovation across The Lancet’s portfolio of clinical journals, helping to shape global medical publishing, research standards, and scientific discourse in oncology. Trained in tumor biology at the Gray Cancer Institute/University College London, he previously held research appointments in therapeutic radiology at Yale University and with the PET Oncology Group at Imperial College London.
He has led and edited The Lancet Oncology’s sustained coverage of global cancer control, health policy, and oncology research in low- and middle-income countries. He is the author of Collingridge dilemma, a methodological quandary that highlights the precautions and risks of technology development and efforts to control it, a concept that gains more traction with time as AI and technology start to establish their place in healthcare and beyond.
The 100 Most Influential People in Oncology in 2025 recognizes the changemakers in cancer care who have helped shape current practice in oncology and continue to drive innovation and research towards better outcomes, advocacy, philanthropy, leadership and education. For the many deserving individuals not mentioned in this list, we will continue to acknowledge, honor and elevate your voices in our daily publications from across the world.
See the full list of The 100 Influential People in Oncology in 2025 and stay tuned for the results of special category nominations to be announced.
